NC
ADMA icon

nVerses Capital’s ADMA Biologics ADMA Stock Holding History

nVerses Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,364
Closed -$201K – 289
2026
Q1 		$201K Buy
22,364
+725
+3% +$11.4K 0.18% 270
2025
Q4 		$395K Buy
+21,639
New +$365K 0.88% 6
2024
Q4 		– Sell
-2,100
Closed -$42K – 12
2024
Q3 		$42K Sell
2,100
-9,400
-82% -$146K 0.02% 681
2024
Q2 		$129K Buy
11,500
+400
+4% +$3.35K 0.08% 370
2024
Q1 		$73.3K Buy
+11,100
New +$60.7K 0.18% 216

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

nVerses Capital's ADMA Position: Q2 2026 in Review

nVerses Capital sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 22,364 shares — an estimated $201K sold.

nVerses Capital first reported a position in ADMA in Q1 2024 and held it in 5 quarters. The position peaked at $395K in Q4 2025. 241 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • nVerses Capital reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 22,364 ADMA Biologics shares in Q2 2026, an estimated $201K.
  • nVerses Capital first reported a position in ADMA Biologics in Q1 2024 and held it in 5 quarters.
  • nVerses Capital's ADMA Biologics position peaked at $395K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.